Mirtazapina Teva-Ratio (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Teva‑Ratio, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and works by influencing neurotransmitter activity to improve mood and alleviate depressive symptoms.

GNH USA supplies Mirtazapina Teva‑Ratio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a tetracyclic antidepressant used primarily in the management of depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depression with insomnia: promotes sleep onset and improves sleep quality. - Depression with anxiety: alleviates anxiety symptoms associated with depressive episodes.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts or behavior, especially early in treatment - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction or elevated liver enzymes - Seizures - Hyponatremia due to SIADH

Before initiating therapy, clinicians should consider several safety aspects. - Assess hepatic function: adjust use in severe liver impairment. - Monitor body weight: significant weight gain can occur. - Evaluate for suicidal ideation: heightened risk at treatment start. - Use caution in elderly patients: increased fall risk due to sedation. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Central nervous system depressants (alcohol, benzodiazepines): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (SSRIs, SNRIs, tramadol): additive serotonergic effects. - Anticholinergic drugs (e.g., diphenhydramine): increased anticholinergic burden. - Warfarin: potential alteration of INR, requiring coagulation monitoring.